Major kidney study 'FLOW' stopped 1 year early due to overwhelmingly positive results. The study is evaluating the effect of medication Semagutide commonly known as Ozempic on the progression of diabetic kidney disease.Major kidney study 'FLOW' stopped 1year early due to overwhelmingly positive results. The study isevaluating the affect of medication Semaglutide, commonly known as Ozempic, onthe progression of kidney disease, results of the study are expected to be publishedearly in
Majr kidney study 'FLOW' stopped 1year early due to overwhelmingly positive results. The study isevaluating the affect of medication SeMmaglutide, commonly known as Ozempic, onthe progression of kidney disease, results of the study are expected to be publishedearly in 2024.
https://www.everydayhealth.com/kidney-diseases/ozempic-is-so-beneficial-for-kidney-health-they-just-stopped-a-major-trial-one-year-early/?_cldee=PBfE3K3FNFT_iiB41V8_0mfDQG5lPHkSfH_uvZCvR2xi451-VgCWtUIQhC91hlOn&recipientid=contact-be4d77e92348ec118c62002248159d41-6d8e2db6bb7943ce8097279d979b29bf&esid=fd7b33d7-d26b-ee11-9ae7-000d3a798fb7
Ann: Sonic Healthcare USA signs licence for PromarkerD in the US, page-68
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
69.5¢ |
Change
0.015(2.21%) |
Mkt cap ! $91.04M | |||
| Open | High | Low | Value | Volume |
| 70.0¢ | 70.0¢ | 69.0¢ | $38.37K | 55.54K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14499 | 69.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 69.5¢ | 2750 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |